Phenotypic Test of Benzo[4,5]imidazo[1,2-c]pyrimidinone-Based Nucleoside and Non-Nucleoside Derivatives against DNA and RNA Viruses, Including Coronaviruses.
RdRp
SARS-CoV-2
antiviral activity
benzo[4,5]imidazo[1,2-c]pyrimidinone
human coronavirus
liquid–liquid phase separation
respiratory syncytial virus
tricyclic nucleoside analogs
varicella zoster virus
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
received:
20
08
2023
revised:
16
09
2023
accepted:
23
09
2023
medline:
1
11
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Emerging and re-emerging viruses periodically cause outbreaks and epidemics around the world, which ultimately lead to global events such as the COVID-19 pandemic. Thus, the urgent need for new antiviral drugs is obvious. Over more than a century of antiviral development, nucleoside analogs have proven to be promising agents against diversified DNA and RNA viruses. Here, we present the synthesis and evaluation of the antiviral activity of nucleoside analogs and their deglycosylated derivatives based on a hydroxybenzo[4,5]imidazo[1,2-c]pyrimidin-1(2H)-one scaffold. The antiviral activity was evaluated against a panel of structurally and phylogenetically diverse RNA and DNA viruses. The leader compound showed micromolar activity against representatives of the family
Identifiants
pubmed: 37834006
pii: ijms241914540
doi: 10.3390/ijms241914540
pmc: PMC10572855
pii:
doi:
Substances chimiques
Nucleosides
0
Antiviral Agents
0
RNA, Viral
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 22-25-00161
Références
J Med Chem. 2000 Dec 28;43(26):4993-7
pubmed: 11150169
Protein Cell. 2021 Sep;12(9):734-740
pubmed: 33770364
Bioorg Med Chem. 2020 Nov 15;28(22):115713
pubmed: 33128910
Nat Commun. 2020 Nov 27;11(1):6041
pubmed: 33247108
Front Microbiol. 2022 Feb 18;13:802671
pubmed: 35250924
Front Genet. 2017 Sep 20;8:125
pubmed: 28979293
Handb Exp Pharmacol. 2009;(189):299-320
pubmed: 19048205
Nat Commun. 2021 Apr 9;12(1):2114
pubmed: 33837182
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4511-3
pubmed: 14643358
Viruses. 2022 Apr 18;14(4):
pubmed: 35458571
Virol J. 2015 Dec 22;12:222
pubmed: 26695637
Viruses. 2022 Feb 12;14(2):
pubmed: 35215972
Int J Microbiol. 2015;2015:769121
pubmed: 25852754
Retrovirology. 2023 Apr 7;20(1):4
pubmed: 37029379
Nat Rev Mol Cell Biol. 2017 May;18(5):285-298
pubmed: 28225081
Chem Res Toxicol. 1995 Sep;8(6):865-74
pubmed: 7492736
Viruses. 2022 Apr 07;14(4):
pubmed: 35458500
Biochem Biophys Res Commun. 2021 Feb 19;541:50-55
pubmed: 33477032
FEBS J. 2023 Jan;290(1):80-92
pubmed: 35916766
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3385-8
pubmed: 23623492
Nat Rev Microbiol. 2011 Oct 17;9(12):860-75
pubmed: 22002165
Eur J Med Chem. 2015 Jun 5;97:388-96
pubmed: 25576500
Antiviral Res. 2018 Jun;154:66-86
pubmed: 29649496
ChemistryOpen. 2016 Jan 21;5(3):227-35
pubmed: 27551659
Chem Heterocycl Compd (N Y). 2020;56(6):636-643
pubmed: 32836313
Front Chem. 2016 Apr 28;4:19
pubmed: 27200341
Int J Mol Sci. 2022 Dec 03;23(23):
pubmed: 36499608
Nat Rev Drug Discov. 2013 Jun;12(6):447-64
pubmed: 23722347
Front Immunol. 2023 May 10;14:1162211
pubmed: 37251408
PLoS Med. 2011 May;8(5):e1000436
pubmed: 21629683
Antiviral Res. 2019 Feb;162:5-21
pubmed: 30529089
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
pubmed: 22446091
Antiviral Res. 2013 May;98(2):242-7
pubmed: 23470860
Viruses. 2021 Apr 13;13(4):
pubmed: 33924302
Nucleic Acids Res. 2022 Aug 12;50(14):8168-8192
pubmed: 35871289
Int J Mol Sci. 2023 Feb 08;24(4):
pubmed: 36834771
Mol Biol. 2021;55(6):786-812
pubmed: 34955556
Trends Microbiol. 2018 Oct;26(10):865-876
pubmed: 29759926
Antiviral Res. 2019 Mar;163:117-124
pubmed: 30684562
J Biol Chem. 2022 Mar;298(3):101677
pubmed: 35131265
Front Immunol. 2022 Aug 09;13:985622
pubmed: 36016945